Table 1.
Association of BRCA1/2 germline mutations with race and tumor characteristics (combined three cohorts, N = 1240)
| Variable | WT/benign/likely benigna | VUSb | Pathogenicc | P value |
|---|---|---|---|---|
| Race | ||||
| AA | 412 (94.1) | 20 (4.6) | 6 (1.4) | 0.0063 |
| CA | 750 (97.4) | 12 (1.6) | 8 (1.0) | |
| Clinical stage | ||||
| Early stage (T2) | 984 (96.5) | 29 (2.8) | 7 (0.7) | 0.0206 |
| Advanced stage (T3–4/N1/M1/D3) | 182 (94.3) | 5 (2.6) | 6 (3.1) | |
| Biopsy Gleason sum | ||||
| 6 or less | 659 (96.6) | 19 (2.8) | 4 (0.6) | 0.0331 |
| 7 | 317 (95.5) | 11 (3.3) | 4 (1.2) | |
| 8–10 | 169 (95.5) | 2 (1.1) | 6 (3.4) | |
Numbers in parenthesis indicate % values
aWild type BRCA1/2 and benign/likely benign mutations in BRCA1/2
bVariants of unknown significance in BRCA1/2
cPathogenic mutations in BRCA1/2